These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22704290)

  • 21. Quantitative interpretation of human biomonitoring data.
    Clewell HJ; Tan YM; Campbell JL; Andersen ME
    Toxicol Appl Pharmacol; 2008 Aug; 231(1):122-33. PubMed ID: 18589468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective.
    Hays SM; Becker RA; Leung HW; Aylward LL; Pyatt DW
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):96-109. PubMed ID: 17030369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomonitoring Equivalents for bisphenol A (BPA).
    Krishnan K; Gagné M; Nong A; Aylward LL; Hays SM
    Regul Toxicol Pharmacol; 2010 Oct; 58(1):18-24. PubMed ID: 20541576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
    Paciorek CJ; Liu Y;
    Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP).
    Aylward LL; Hays SM; Gagné M; Krishnan K
    Regul Toxicol Pharmacol; 2009 Dec; 55(3):259-67. PubMed ID: 19751787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling.
    Tan YM; Liao KH; Clewell HJ
    J Expo Sci Environ Epidemiol; 2007 Nov; 17(7):591-603. PubMed ID: 17108893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derivation of Biomonitoring Equivalents for cyfluthrin.
    Hays SM; Aylward LL; Gagné M; Krishnan K
    Regul Toxicol Pharmacol; 2009 Dec; 55(3):268-75. PubMed ID: 19751788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidance values for the biomonitoring of occupational exposure. State of the art.
    Aitio A
    Med Lav; 2006; 97(2):324-31. PubMed ID: 17017366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
    Kirman CR; Sweeney LM; Corley R; Gargas ML
    Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop.
    Hays SM; Aylward LL; LaKind JS; Bartels MJ; Barton HA; Boogaard PJ; Brunk C; DiZio S; Dourson M; Goldstein DA; Lipscomb J; Kilpatrick ME; Krewski D; Krishnan K; Nordberg M; Okino M; Tan YM; Viau C; Yager JW;
    Regul Toxicol Pharmacol; 2008 Aug; 51(3 Suppl):S4-15. PubMed ID: 18583008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomonitoring equivalents for di-isononyl phthalate (DINP).
    Hays SM; Aylward LL; Kirman CR; Krishnan K; Nong A
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):181-8. PubMed ID: 21466828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context.
    St-Amand A; Werry K; Aylward LL; Hays SM; Nong A
    Toxicol Lett; 2014 Dec; 231(2):126-34. PubMed ID: 25455445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomonitoring Equivalents (BE) dossier for trihalomethanes.
    Aylward LL; LaKind JS; Hays SM
    Regul Toxicol Pharmacol; 2008 Aug; 51(3 Suppl):S68-77. PubMed ID: 18579267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A spreadsheet program for modeling quantitative structure-pharmacokinetic relationships for inhaled volatile organics in humans.
    Béliveau M; Krishnan K
    SAR QSAR Environ Res; 2005; 16(1-2):63-77. PubMed ID: 15844443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomonitoring Equivalents for triclosan.
    Krishnan K; Gagné M; Nong A; Aylward LL; Hays SM
    Regul Toxicol Pharmacol; 2010 Oct; 58(1):10-7. PubMed ID: 20541577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
    Allen BC; Hack CE; Clewell HJ
    Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human biomonitoring: state of the art.
    Angerer J; Ewers U; Wilhelm M
    Int J Hyg Environ Health; 2007 May; 210(3-4):201-28. PubMed ID: 17376741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
    Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
    Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Acute Exposure Guideline Level (AEGL) program: applications of physiologically based pharmacokinetic modeling.
    Bruckner JV; Keys DA; Fisher JW
    J Toxicol Environ Health A; 2004 Apr 23-May 28; 67(8-10):621-34. PubMed ID: 15192858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomonitoring equivalents for hexachlorobenzene.
    Aylward LL; Hays SM; Gagné M; Nong A; Krishnan K
    Regul Toxicol Pharmacol; 2010 Oct; 58(1):25-32. PubMed ID: 20547196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.